NCT04459065
Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Recruiting
- Notable Primary completion date: Sep 2023 to Sep 2026
- Study completion date: Mar 2024 to Oct 2026
- Notable Primary completion date: Sep 2022 to Sep 2023
- Study completion date: Sep 2022 to Mar 2024
- Minor Start date changed from estimate of Sep 2020 to Sep 1, 2020v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Aug 2022 to Sep 2022
- Start date: Aug 2020 to Sep 2020
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Participants will receive an i.v. infusion of 50 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
Participants will receive an i.v. infusion of 100 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on results from cohorts 1 and 2). Participants will undergo lung cancer resection surgery 1-3 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on cohorts 1 and 2). Participants will undergo lung cancer resection surgery 7+ days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
Drugs: IRDye800CW-nimotuzumab
Sites
1 site in 1 country
- St. Paul's HospitalSaskatoon, Saskatchewan, Canada